X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Korlym (mifepristone) is a selective antagonist of the progesterone receptor at low doses and blocks the GR-II at higher doses. It is being evaluated for the treatment of cushing syndrome.
Lead Product(s): Mifepristone
Therapeutic Area: Endocrinology Product Name: Korlym
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2024
Details:
Korlym (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance.
Lead Product(s): Mifepristone
Therapeutic Area: Endocrinology Product Name: Korlym
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2024
Details:
FloraStilbene (mifepristone and pterostilbene) to stimulate the immune system in advanced breast cancer patients. Preclinical data demonstrated that FloraStilbene overcame immune suppression induced in the 4T1 mouse model of triple negative breast cancer.
Lead Product(s): Mifepristone,Pterostilbene
Therapeutic Area: Oncology Product Name: FloraStilbene
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2024
Details:
FloraStilbene (RU486 and pterostilbene) to stimulate the immune system in advanced breast cancer patients. Preclinical data demonstrated that FloraStilbene overcame immune suppression induced in the 4T1 mouse model of triple negative breast cancer.
Lead Product(s): Mifepristone,Pterostilbene
Therapeutic Area: Oncology Product Name: FloraStilbene
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2023
Details:
Under the collaboration, Cure Stat Rx will manufacture first in class breast cancer immunotherapy product FloraStilbene™ for a planned 12 patient Phase I/II trial aimed at assessing immunomodulatory activity of the drug candidate in advanced breast cancer patients.
Lead Product(s): Mifepristone,Pterostilbene
Therapeutic Area: Oncology Product Name: FloraStilbene
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cure Stat Rx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 15, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
